Indian Glivec patent battle moves to Supreme Court
This article was originally published in Scrip
Executive Summary
Novartis has filed a special leave petition with India's Supreme Court challenging the denial of a patent on the beta crystal form of its anticancer, Glivec (imatinib mesilate).